Energy drinks appear 11 times more often in cardiac arrest reports, preliminary study finds
University of Virginia researchers analysed FDA adverse-event reports for foods and supplements from 2017 to 2025.
University of Virginia researchers analysed FDA adverse-event reports for foods and supplements from 2017 to 2025.
On 18 November 2026 the FDA approved Sanofi's Infilbray (venglustat).
On 17 November 2026 the FDA granted accelerated approval to Nelkarmi (neladalkib).
On 9 November 2026 the FDA approved Bayer's Sunharbo (asundexian).
On 26 October 2026 the FDA approved Talzenna (talazoparib) with enzalutamide for metastatic prostate cancer.
Macleods Pharma USA is recalling 3,744 bottles of olmesartan, amlodipine and hydrochlorothiazide tablets for high blood pressure.
Apothecary Pharma is recalling 22 vials of compounded tirzepatide and one vial of NAD+ injection because their sterility cannot be assured.
On 20 October 2026 the FDA approved GSK's Hibsago (bepirovirsen) injection for chronic hepatitis B.
On 19 October 2026 the FDA granted accelerated approval to Jemperli (dostarlimab) for stage II/III locally advanced rectal cancer.
On 14 October 2026 the FDA expanded the approval of Anktiva (nogapendekin alfa inbakicept-pmln) with BCG for non-muscle invasive bladder cancer.
Nothing more to show